Technical bulletin from state health officials provides clinical guidance The U.S. Food and Drug Administration (FDA) has authorized the emergency use of the Moderna COVID-19 vaccine and the Pfizer-BioNTech COVID-19 vaccine for the prevention of COVID-19 to include use in children under 5 years of age.
On June 18, the day after FDA authorization, the Advisory Committee on Immunization Practices (ACIP) unanimously voted to recommend the use of the Moderna COVID-19 vaccine two-dose primary series for children ages 6 months to 5 years and the Pfizer three-dose series for children ages 6 months to 4 years. According to disease burden data to the ACIP, children ages 6 months through 4 years are at risk of severe COVID -19 infection and more than 2 million cases of the illness have been identified among this population. COVID-19-associated hospitalizations among children ages 6 months through 4 years have similar severity compared to older children and adolescents and more than half of the hospitalized children ages 6 months through 4 years had no underlying conditions. The burden of COVID-19associated death among this population is similar to or exceeds that of other pediatric vaccine-preventable diseases. For more information, including vaccine administration guidance, see the technical bulletin on this topic posted to the Division of Public and Behavioral Health Technical Bulletins web page.
0 Comments
Leave a Reply. |
AuthorThe Bureau of Health Care Quality and Compliance (HCQC) licenses medical and other health facilities, child care facilities and personnel, and medical laboratories and personnel in Nevada. HCQC also conducts compliance surveys and takes complaints. Archives
October 2023
Categories
All
|